基于文献计量学的贝林妥欧单抗治疗急性淋巴细胞白血病的研究现状分析★

Bibliometrics-based analysis of the current state of research on blinatumomab for acute lymphoblastic leukemia★

摘要:

目的 探讨近10年贝林妥欧单抗治疗急性淋巴细胞白血病的研究现状、趋势及热点。方法 检索CNKI数据库、Web of Science核心合集数据库2014—2023年收录的贝林妥欧单抗治疗急性淋巴细胞白血病相关文献，运用CiteSpace 6.1.R6软件进行可视化分析。结果 CNKI数据库共纳入中文文献8篇，发文量呈逐年上升趋势，但因纳入文献数量不足，未能进行可视化分析。Web of Science核心合集数据库共纳入英文文献784篇，涉及62个国家、331个机构。发文量最多的作者为Elias Jabbour，共37篇；发文量最多的国家是美国，共454篇；发文量最多的机构是美国MD安德森癌症中心，共97篇。排名第1的高频关键词为微小残留病灶，关键词突现显示目前儿童仍具有突现性。共被引频次排名前10的文献中，有4篇报道了贝林妥欧单抗治疗急性淋巴细胞白血病的疗效。共被引文献以关键词聚类形成8大主题，目前比较活跃的聚类是儿童和酪氨酸酶抑制剂。结论 近10年贝林妥欧单抗治疗急性淋巴细胞白血病的研究主要集中于其在儿童群体中的有效性和安全性，目前的研究热点仍是儿童群体，未来的研究趋势为贝林妥欧单抗与奥加伊妥珠单抗、酪氨酸激酶抑制剂等联合用药。

Abstract:

Objective To explore the current research status, trends and hotspots of blinatumomab in the treatment of acute lymphoblastic leukemia in the past 10 years.Methods The related literature on blinatumomab in the treatment of acute lymphoblastic leukemia was retrieved from the CNKI database and Web of Science Core Collection database from 2014 to 2023. The literature was visualized and analyzed using CiteSpace 6.1.R6 software.Results The CNKI database included a total of 8 Chinese articles, showing an increasing trend in publication volume year by year. However, due to insufficient literature inclusion, visual analysis could not be performed. The Web of Science Core Collection database included a total of 784 English articles from 62 countries and 331 institutions. Jabbour Elias was the author who has published the most articles in this field, with a total of 37, and the Anderson Cancer Center in the United States was the institution that published the most, with a total of 97. The United States contributed the most articles (454) among the countries. The top frequent keyword was minimal residual disease, and the keyword surge indicates that children still have a sudden emergence. Among the top ten most cited articles, four reported on the efficacy of blinatumomab in the treatment of acute lymphoblastic leukemia. The cited literature formed eight major themes through keyword clustering, and currently the most active clustering is children and tyrosine kinase inhibitors.Conclusion In the past 10 years, the research on blinatumomab in the treatment of acute lymphoblastic leukemia has mainly focused on its effectiveness and safety in pediatric populations. Current research hotspots continue to center around pediatric populations, with future trends pointing towards combination therapies involving blinatumomab alongside inotuzumab ozogamicin or tyrosine kinase inhibitors.